Linked Life Data

2874169

Source:http://linkedlifedata.com/resource/pubmed/id/2874169

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1986-9-17
pubmed:abstractText
In recent years, many new systemic medications have been developed as potential therapies for the patient with chronic GER and esophagitis. Despite these therapeutic advances, large numbers of GER patients continue to have chronic symptoms or unresolved complications. To some degree, this may relate to uncertainties regarding the pathogenesis of GER and its complications; i.e., is it primarily due to acid/pepsin injury or to primary motility disorders in the esophagus. Many new therapies are currently being developed, particularly those with the potential ability to enhance esophageal contractions--the prokinetic drugs. The main potential therapies of GER are discussed, including possible new acid suppression therapies, new anticholinergic drugs, new prokinetic drugs, and medications that might enhance the mucosal barrier. In addition, the more complex questions of effectiveness of chronic medical versus surgical therapy, and the use of combined medical therapies, are discussed.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0192-0790
pubmed:author
pubmed:issnType
Print
pubmed:volume
8 Suppl 1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
81-5
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
1986
pubmed:articleTitle
Future medical therapy of reflux esophagitis.
pubmed:publicationType
Journal Article